South Korea’s GC Pharma has agreed to produce Covid-19 vaccines being developed by one of multinational pharmaceutical companies for countries participating in the Coalition for Epidemic Preparedness Innovations (CEPI), an international public-private partnership to accelerate the development of a vaccine for the novel coronavirus.

According to industry sources on Thursday, GC Pharma and CEPI recently reached an agreement over commissioned vaccine production in Korea, but details have yet to be worked out regarding which vaccine brand and how many doses will be produced.

GC Pharma said they are now in a pre-agreement stage and a definitive contract will follow to fix the production volume with a vaccine developer.

GC Pharma’s commissioned production will begin in March 2021 and end in May 2022, according to sources. CEPI aims to produce 500 million doses during this term.

At its full capacity, GC Pharma is capable to produce 400 million vaccine doses per year.

The CEPI established at 2017 Davos World Economic Forum is a leading private body for COVAX vaccine research and development work to ensure safe, effective, and equitable vaccine delivery to countries participating in the COVAX Facility.

By Pulse

[ⓒ Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]